NCT03875820: Phase I Trial of VS-6063 and RO5126766.

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, KRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a RAS mutant solid tumor
Exclusions: Patients with known untreated or active central nervous system (CNS) metastases (progressing or requiring corticosteroids for symptomatic control)- see trial for details

Comments are closed.

Up ↑